S&P 5007,376.86+0.31%DOW51,285.73-0.46%NASDAQ24,579.42+1.09%BTC$75,946.00-0.25%ETH$2,243.57+0.21%GOLD$4,079.50-0.83%OIL$90.34-0.20%

NYSE · BSX

Boston Scientific Corporation

Healthcare · Medical - Devices

$42.75

Down-$1.89 (-4.23%)

Updated Nov 8, 2026, 5:59 AM

SID Score

5.2/10

Composite research score

Smart Money

56/100

Neutral

Market cap: 135.98B
P/E ratio: 48.75
Dividend yield: 0.00%
52-week range: $39.57 – $99.09
Volume: 14.71M
Avg. volume: 9.87M

Price performance · BSX

BSX price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 6, 2026

Last close: $42.75
Period change: -2.49%
Period low: $41.98
Period high: $46.01

Daily close

View OHLC price history

BSX OHLC price history, latest 40 sessions
Date	Open	High	Low	Close	Volume
Nov 6, 2026	$43.35	$43.63	$42.69	$42.75	14.71M
Nov 5, 2026	$46.585	$46.85	$43.895	$44.64	22.49M
Nov 4, 2026	$44.805	$46.97	$44.76	$45.82	34.56M
Nov 3, 2026	$43.87	$44.615	$43.21	$43.50	18.89M
Nov 2, 2026	$42.07	$44.365	$41.90	$44.32	22.71M
Oct 30, 2026	$42.95	$43.29	$41.725	$41.98	22.47M
Oct 29, 2026	$41.81	$43.085	$41.675	$42.69	31.76M
Oct 28, 2026	$41.95	$43.915	$39.57	$42.43	69.84M
Oct 27, 2026	$45.29	$45.33	$44.855	$45.06	15.14M
Oct 26, 2026	$45.31	$46.07	$45.125	$45.58	11.93M
Oct 23, 2026	$45.84	$46.16	$45.215	$45.69	8.77M
Oct 22, 2026	$44.72	$46.05	$44.62	$46.01	16.4M
Oct 21, 2026	$45.04	$45.64	$43.915	$44.51	15.19M
Oct 20, 2026	$45.67	$46.045	$45.15	$45.58	16.01M
Oct 19, 2026	$44.01	$45.10	$43.935	$45.05	13.97M
Oct 16, 2026	$44.45	$44.8314	$43.89	$44.39	12.41M
Oct 15, 2026	$43.945	$44.43	$43.46	$44.14	15.87M
Oct 14, 2026	$43.40	$43.5785	$42.28	$43.00	15.1M
Oct 13, 2026	$43.95	$44.1522	$42.455	$43.31	14.28M
Oct 12, 2026	$43.10	$43.92	$42.67	$43.84	13.6M

Latest BSX news

The latest Smart Investors Daily articles mentioning BSX.

Featured By

Inc.

Nasdaq

Filter news

Filters are reflected in the page URL for sharing and back-button support.

BSX news

5 matching articles.

Yahoo · Nov 6, 2026

S&P revises Boston Scientific outlook to negative on franchise pressures

Investing.com -- S&P Global Ratings has revised its outlook on Boston Scientific Corp. to negative from stable, warning that deepening commercial headwinds across its core product franchises will likely keep financial leverage stretched through 2028. While the rating agency affirmed the medical device maker’s ’A-’ issuer credit rating and senior unsecured debt rating, S&P highlighted that deteriorating top-line momentum coincides with the balance-sheet burden of its pending $14.5 billion acquisi

Benzinga · Nov 4, 2026

Here’s How Much You Would Have Made Owning Boston Scientific Stock In The Last 15 Years

Boston Scientific (NYSE:BSX) has outperformed the market over the past 15 years by 1.84% on an annualized basis producing an average annual return of 14.73%. Currently, Boston Scientific has a market capitalization of

Yahoo · Nov 5, 2026

Here is What to Know Beyond Why Boston Scientific Corporation (BSX) is a Trending Stock

Boston Scientific (BSX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Yahoo · Nov 5, 2026

Boston Scientific, Blackstone agree to $455M deal to co-fund heart pump development

As part of the agreement, Blackstone may receive regulatory and commercial milestone payments, plus royalties on net sales.

Yahoo · Nov 4, 2026

RevMedica Appoints Former Boston Scientific Executive Mike Jones as Chief Executive Officer

RevMedica, an innovative medical technology company developing intelligent surgical stapling solutions, today announced the appointment of Mike Jones as Chief Executive Officer and a member of its Board of Directors. Jones succeeds RevMedica founder Tom Wenchell, who will transition to President and Chief Operating Officer, continuing to lead product development, technical operations, and day-to-day business execution.